Physician
Pulmonology
Dr. Bruce L. Davidson, MD
Doctor Bruce L. Davidson, MD works in the field of Pulmonology. He studied medicine at Temple University School of Medicine. Bruce Davidson is also published. He has 73 publications published. The lastest publication: "Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.' Bruce L. Davidson is registered with Medicare and accepts Medicare payments.
Publications
- Dalteparin and heparin-induced thrombocytopenia.
- Prevalence and Risk of Pre-existing Heparin-induced Thrombocytopenia Antibodies in Patients with Acute Venous ThromboEmbolism.
- Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants.
- Why can't magnetic resonance imaging reliably diagnose Pulmonary embolism?
- Vena cava filter occlusion and venous thromboEmbolism risk in persistently anticoagulated patients: a prospective, observational cohort study.
- Half the dosage, similar efficacy, less bleeding: the new tissue plasminogen activator regimen for Pulmonary embolism?
- Pulmonary embolism in the critically ill.
- Targeting the mediastinum: one-stop shopping at all times?
- Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboEmbolism in orthopaedic surgery.
- Resolution of thromboemboli in patients with acute Pulmonary embolism: a systematic review.
- Management of Pulmonary embolism in 2005.
- The economics of venous thromboEmbolism prophylaxis: a primer for clinicians.
- Endoscopic ultrasound, positron emission tomography, and computerized tomography for Lung cancer.
- Ximelagatran versus warfarin for the prevention of venous thromboEmbolism after total knee arthroplasty. A randomized, double-blind trial.
- Low-dose heparin for severe sepsis.
- Introduction--venous thromboEmbolism management in the real world: your opportunity to participate in a critical assessment.
- Oral rivaroxaban for symptomatic venous thromboEmbolism.
- Idraparinux versus standard therapy in the treatment of deep venous thrombosis in Cancer patients: a subgroup analysis of the Van Gogh DVT trial.
- Accuracy of compression ultrasound in screening for deep venous thrombosis in acutely ill medical patients.
- Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboEmbolism after knee arthroplasty surgery.
- A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
- Treatment of venous thromboembolism in patients with Cancer: subgroup analysis of the Matisse clinical trials.
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
- Clinical implications of cytokines in the critical-care unit.
- Efficacy and safety of fondaparinux for the prevention of venous thromboEmbolism in older acute medical patients: randomised placebo controlled trial.
- Preparing for the new anticoagulants.
- Incidence of Chronic thromboembolic pulmonary hypertension after pulmonary embolism.
- Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
- A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboEmbolism: use in patients undergoing major or...
- Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
- Measuring the outcomes and pharmacoeconomic consequences of venous thromboEmbolism prophylaxis in major orthopaedic surgery.
- Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis.
- Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.
- Idraparinux versus standard therapy for venous thromboembolic Disease.
- Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
- Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.
- Extended prophylaxis of venous thromboEmbolism with idraparinux.
- Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the Swedish study.
- Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. The RD Heparin Arthroplasty Group.
- Venous thromboEmbolism and the risk of subsequent symptomatic atherosclerosis.
- The diagnostic approach to acute venous thromboEmbolism. Clinical practice guideline. American Thoracic Society.
- Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of Pulmonary embolism.
- Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboEmbolism following total hip replacement. A randomiz...
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
- Comparison of idraparinux with vitamin K antagonists for prevention of thromboEmbolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority ...
- Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboEmbolism in the Matisse trials.
- Should echocardiography of the right ventricle help determine who receives thrombolysis for Pulmonary embolism?
- Risk assessment and prophylaxis of venous thromboEmbolism in acutely and/or critically ill patients.
- Prolonged prophylaxis after joint replacement: another step sideways?
- Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic Disease.
- Controversies in Pulmonary embolism and deep venous thrombosis.
- DVT treatment in 2000: state of the art.
- What are the most reliable detection methods for deep vein thrombosis and Pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis?
- Monitoring the anticoagulant effects of a low molecular weight heparin preparation. Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for...
- A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States.
- Compliance with recommended prophylaxis for venous thromboEmbolism: improving the use and rate of uptake of clinical practice guidelines.
- When Pulmonary embolism treatment isn't working.
- Ultrasound for the diagnosis of deep vein thrombosis: where to now?
- Applying risk assessment models in non-surgical patients: overview of our clinical experience.
- Expression of human interleukin-1 receptor antagonist in mouse Lungs using a recombinant adenovirus: effects on vector-induced inflammation.
- Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations.
- Looking forward, looking back: assessing variations in hospital resource use and outcomes for elderly patients with heart Failure.
- Workshop II: The future of prolonged thromboprophylaxis.
- Pulmonary inflammation induced by incomplete or inactivated adenoviral particles.
- Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
- Co-occurrence of AIDS and tuberculosis: results of a database "match" and investigation.
- The "Lung shift" in treated schistosomiasis. Bronchoalveolar lavage evidence of eosinophilic pneumonia.
- Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector.
- Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.
- Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.
- Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine.
- Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial.
Schools
Temple University
Procedures Preformed
- Bronchoscopy
- Ventilation Management
Conditions Treated
- Acidosis
- Asthma
- Bronchiectasis
- COPD (Chronic Obstructive Pulmonary Disease)
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Education
-
University of Pennsylvania Health System -
Temple University School of Medicine
Drug Facts
| NPI NUMBER | 1619932092 | |
| NPPES Provider LastName | DAVIDSON | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 981462411 | |
| NPPES Provider State | WA | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 16.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1619932092 |
| Last Name Of The Provider | DAVIDSON |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
Dr. Daniel M. Talley, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Scott Slaymaker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederic N. Jackson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert L. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nithya K. Iyer, MD
This Doctor is OpenDoctor Recommended.
|